CDK4 and neoplasm: In CDK4/6i-treated patients, ctDNA has been exploited to detect biomarkers of de novo resistance, to assess dynamics of genomic alterations during CDK4/6i administration and to evaluate biomarkers of acquired resistance at the time of tumor progression.